Online inquiry

IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15601MR)

This product GTTS-WQ15601MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLC29A2 gene. The antibody can be applied in Glycogen storage disease type II (GSD-II) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15601MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9849MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ8682MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ871MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ8748MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ8805MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ10513MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ5966MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ7291MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW